State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

We’re working to bring the hope of advanced medicine to more patients.

Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.

Gschwentner and Lackner discuss the advantages of their job share.

The culture of volunteerism is a fundamental part of the Novartis corporate ethos. Here’s a snapshot of our efforts over the years.

Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.